BeneFIX® offers efficacy when you and your patients need it most.1-3
BeneFIX® proven efficacy across a wide range of patients,1,4* including paediatric patients.2-5
Prophylaxis
BeneFIX® has proven efficacy in prophylaxis1,2
On-demand Treatment
On-demand Treatment
Surgical Efficacy
Overall, 96.7% of responses were rated excellent or good in PUPs receiving BeneFIX® and undergoing surgery.2
A total of 30 surgical procedures including 12 permanent venous access placements, 7 circumcisions, 1 dental procedure and 10 other procedures.2
Study description (PTPs)
A 20-centre international trial was conducted in PTPs with severe or moderate (<5 IU/dL FIX activity) hemophilia B. Participants received rFIX for PK studies, treatment of or prophylaxis against haemorrhage, or surgical hemostasis, and were assessed at 3-month intervals for 2 years.1
Study description (PUPs)
A multicentre, international, open-label, single-cohort study consisting of a core phase and an extension phase. In the core phase, patients received rFIX for (1) on-demand treatment in response to any bleeding episode, (2) routine prophylaxis or (3) surgical prophylaxis. Patients who completed the core phase (2 years, up to a maximum of 5 years or 100 exposure days) were allowed to enter the extension phase to receive rFIX for up to 1 additional year, at the discretion of the investigator and after prior written authorisation from the sponsor.2
BeneFIX® has proven efficacy in surgery3
Activity and Joint Health
Higher and more frequent peak factor levels may be needed for some patients.9
The importance of peak and trough levels in hemophilia patients is still not clearly understood. However, studies suggest that higher trough levels and greater area under the curve may correlate to fewer bleeds, especially in joints.8
In patients with more sedentary lifestyles, longer doses may be acceptable.9
In patients with a less than average half-life prolongation, target joints¶ or more on-the move lifestyles, higher and more frequent peak factor levels may be beneficial for sufficient bleed protection.9
The role of peak and trough levels in prophylaxis10,11
(For illustrative purposes only)
Prophylaxis 2x per week (SHL)
Adapted from Mahdi AJ, et al. 2015; Powell JS, et al. 2013.
Prophylaxis 1x per week (EHL)
Adapted from Mahdi AJ, et al. 2015; Powell JS, et al. 2013.
Known benefits of early prophylaxis
Patients who started prophylaxis early (<4 years) is associated with better joint outcomes13
Patients who start prophylaxis soon after the first joint bleed show little arthropathy in adulthood13
Preventing or reducing the clinical impact of haemophilic arthropathy by prophylaxis means14,15:
Possibility of regular school attendance
Social and work opportunities
*Patients with moderate or severe hemophilia B (aged 3-69 years), previously untreated patients, previously treated with high-purity, monoclonal antibody-purified factor IX (pdFIX).
†The response to secondary prophylaxis was assessed once every 3 months by the investigator using a 3-point scale: excellent (no spontaneous bleeding of any kind, no change in dosing regimen necessary); effective (no spontaneous musculoskeletal bleeding, no change in dosing regimen necessary); or inadequate (inadequate prevention of bleeding requiring a change in dosing regimen).1
‡Rated by the investigator at 3-month intervals on a 3-point scale: excellent (prophylaxis treatment completely prevented spontaneous musculoskeletal bleeding, no change in dosing regimen necessary); effective (adequately prevented spontaneous musculoskeletal bleeding episodes as demonstrated by a lower than expected incidence of spontaneous musculoskeletal bleeding episodes); or inadequate (inadequate prevention of bleeding requiring a change in dosing regimen).2
§Haemostasis was rated as excellent or good in 34 out of 35 of the operative procedures. Response ratings are defined as follows: excellent if the response was as satisfactory, with as much and as rapid an improvement as the best responses with other FIX products for similar bleeds or procedures; good if the response was as satisfactory, with as much and as rapid an improvement as most responses with other FIX products for similar bleeds or procedures; moderate if the response was less than satisfactory and not as good as most responses seen with other FIX products when used for similar bleeding episodes or similar procedures; or no response if no improvement at all was observed.3
ǁOverall, 29% (8/28) of patients (9 operative procedures) received postoperative BeneFIX® by continuous infusion.3 BeneFIX® is not licensed for use by continuous infusion – please refer to the BeneFIX® LPD for further information.7
¶A target joint is a joint in which 3 or more spontaneous bleeds have occurred within a consecutive 6-month period.12
EHL, extended half-life; FIX, factor IX; LPD, local prescribing document; PK, pharmacokinetic; PTP, previously treated patient; PUP, previously untreated patient; rFIX, recombinant factor IX; SHL, standard half-life.
References:
PP-BEN-IND-0025 22/07/22
BeneFIX® is a recombinant coagulation FIX. Find out how BeneFIX® works
Learn more
BeneFIX® provides dosing options based on individual needs
Learn more
Proven efficacy and protection across dosing regimen
Review efficacy profile
See how BeneFIX® performs in real-life settings.
Review real-world data
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.
Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.
Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered medical practitioner*, please visit https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 26th April 2021.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.